Tranexamic Acid and Cancer Recurrence after Gastrointestinal Cancer Surgery; A nested substudy of the Tranexamic Acid to Reduce Infection After Gastrointestinal Cancer Surgery (TRIGS) trial

ABSTRACT: Interventions: This substudy nested within the multicentre, pragmatic, double-blind, randomised TRIGS trial NCT04192435. Assessment will be completed once at 5 years post operatively via cancer registry and the National Death Index (NDI will compare cancer-free survival in patients receiving tranexamic acid, or matched p)lacebo, for gastrointestinal cancer surgery. All adult patients scheduled for elective or semi-elective open or lap-assisted gastrointestinal cancer surgery (oesophageal, gastric, hepatobiliary, pancreatic, colorectal) with one or more risk factors for complications, will be included. Primary outcome(s): Cancer-free survival form state cancer registries[5 years from Gastrointestinal surgery] Study Design: Purpose: Natural history;Duration: Longitudinal;Selection: Defined population;Timing: Prospective

DISEASE(S): Cancer-bowel-anal,Cancer-bowel-small Bowel (duodenum And Ileum),Colorectal Cancer,Hepatobiliary Cancer,Cancer-oesophageal (gullet),Pancreatic Cancer,Cancer Recurrence,Cancer-liver,Cancer-biliary Tree (gall Bladder And Bile Duct),Cancer-pancreatic,Oesophageal Cancer,Cancer-stomach,Gastric Cancer,Cancer-bowel-back Passage (rectum) Or Large Bowel (colon)

PROVIDER: 2754854 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR